Glenmark Pharmaceuticals Receives Approval For Multiple Sclerosis Drug

Glenmark Pharmaceuticals Inc., USA has informed that it has received the regulatory approvals for Dimethyl Fumarate delayed-release capsules by the US Food and Drug Administration (FDA). The capsules which have got approval for 120mg and 240mg, can be used for the treatment of relapsing forms of multiple sclerosis. Multiple sclerosis is a chronic illness of central nervous system that affects the brain, spinal cord, and optic nerves.